Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Meta-analysis of incidence of rare events.

Lane PW.

Stat Methods Med Res. 2013 Apr;22(2):117-32. doi: 10.1177/0962280211432218. Epub 2012 Jan 4. Review.

PMID:
22218366
2.

Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.

Dahabreh IJ, Economopoulos K.

Clin Trials. 2008;5(2):116-20. doi: 10.1177/1740774508090212. Erratum in: Clin Trials. 2008;5(5):559. Economopoulos, K [added].

PMID:
18375649
3.

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.

Diamond GA, Bax L, Kaul S.

Ann Intern Med. 2007 Oct 16;147(8):578-81. Epub 2007 Aug 6.

PMID:
17679700
4.

Rosiglitazone and cardiovascular risk.

Diamond GA, Kaul S.

N Engl J Med. 2007 Aug 30;357(9):938-9; author reply 939-40. No abstract available.

PMID:
17806135
5.

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Nissen SE, Wolski K.

N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21. Erratum in: N Engl J Med. 2007 Jul 5;357(1):100..

6.

Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone.

Hernandez AV, Walker E, Ioannidis JP, Kattan MW.

Am Heart J. 2008 Jul;156(1):23-30. doi: 10.1016/j.ahj.2008.03.002. Epub 2008 May 5. Review.

PMID:
18585493
7.
8.

Rosiglitazone and cardiovascular risk.

Psaty BM, Furberg CD.

N Engl J Med. 2007 Jun 14;356(24):2522-4. Epub 2007 May 21. No abstract available.

9.

Faster publication isn't always better.

Fuster V, Farkouh ME.

Nat Clin Pract Cardiovasc Med. 2007 Jul;4(7):345. No abstract available.

PMID:
17589426
10.

Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.

Nagajothi N, Adigopula S, Balamuthusamy S, Velazquez-Cecena JL, Raghunathan K, Khraisat A, Singh S, Molnar J, Khosla S, Benatar D.

Am J Ther. 2008 Nov-Dec;15(6):506-11. doi: 10.1097/MJT.0b013e318167180c.

PMID:
19127132
11.

Rosiglitazone: a thunderstorm from scarce and fragile data.

Mulrow CD, Cornell J, Localio AR.

Ann Intern Med. 2007 Oct 16;147(8):585-7. No abstract available.

PMID:
17938398
12.

The record on rosiglitazone and the risk of myocardial infarction.

Psaty BM, Furberg CD.

N Engl J Med. 2007 Jul 5;357(1):67-9. Epub 2007 Jun 5. No abstract available.

13.

Rosiglitazone and cardiovascular risk.

Bracken MB.

N Engl J Med. 2007 Aug 30;357(9):937-8; author reply 939-40. No abstract available.

14.

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].

PMID:
22118894
15.

Rosiglitazone and cardiovascular risk.

Mannucci E, Monami M, Marchionni N.

N Engl J Med. 2007 Aug 30;357(9):938; author reply 939-40. No abstract available.

PMID:
17806136
16.

Analytical issues regarding rosiglitazone meta-analysis.

Claggett B, Wei LJ.

Arch Intern Med. 2011 Jan 24;171(2):179-80; author reply 180. doi: 10.1001/archinternmed.2010.508. No abstract available.

PMID:
21263111
17.

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

Loke YK, Kwok CS, Singh S.

BMJ. 2011 Mar 17;342:d1309. doi: 10.1136/bmj.d1309. Review.

18.

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Nissen SE, Wolski K.

Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207. Review.

PMID:
20656674
19.

Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Di Bari M, Lamanna C, Gori F, Gensini GF, Marchionni N.

Int J Cardiol. 2010 Aug 20;143(2):135-40. doi: 10.1016/j.ijcard.2009.01.064. Epub 2009 Mar 27.

PMID:
19328563
20.

Rosiglitazone and cardiovascular disease: a cardiologist's perspective.

Marx N.

Diab Vasc Dis Res. 2007 Jun;4(2):80-1. No abstract available.

PMID:
17654439

Supplemental Content

Support Center